Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists-Reference-Cited by-同舟云学术

Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists

Published:2014-12 Issue:6 Volume:66 Page:1101-1108
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Klotz Laurence,Miller Kurt,Crawford E. David,Shore Neal,Tombal Bertrand,Karup Cathrina,Malmberg Anders,Persson Bo-Eric

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008

2. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics;Tombal;Eur Urol,2010

3. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide;Axcrona;BJU Int,2012

4. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233);Anderson;Urol Int,2013

5. Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk;Clinical Pharmacology in Drug Development;2024-05-17

2. Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study;Frontiers in Oncology;2024-02-20

3. Identification of Factors Contributing to Testosterone Recovery After Hormone Therapy Combined With External Radiation Therapy;In Vivo;2024

4. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2023-08

5. A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy;Japanese Journal of Clinical Oncology;2023-07-05